Panacea Biotec Pharma Baddi facility gets 9 USFDA observations

Published On 2023-10-13 06:00 GMT   |   Update On 2023-10-13 07:08 GMT
Advertisement

Punjab: Panacea Biotec Limited has announced that the Company’s material wholly-owned subsidiary, Panacea Biotec Pharma Limited (“PBPL”) has received nine observations from the United States Food and Drug Administration (USFDA) for the Baddi facility at the end of the inspection.

The inspection was held between October 03, 2023 and October 12, 2023.

"At the end of the inspection, PBPL was issued an ‘FDA Form 483’ with nine (9) observations which are related to improvements in existing procedures and are addressable. PBPL will respond to the US FDA within the stipulated time and work closely with US FDA to close the said observations," Panacea informed in a BSE filing.

Advertisement

Read also: Panacea Biotec gets UNICEF, PAHO awards for supply of liquid Pentavalent vaccine Easyfive-n

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

"We are committed to patient safety and quality and take quality and compliance matters seriously and stand by our commitment to fully comply with the cGMP quality standards," the Company added.

Read also: Panacea Biotec arm gets USFDA OAI status for Baddi facility

Panacea Biotec is an Innovation driven Biotechnology company doing Research and Development, Manufacturing, Sales, Distribution and Marketing of Pharmaceuticals and Vaccines.

Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private Limited. It got publically listed on Indian National Stock Exchanges in September 1995 as Panacea Biotec Ltd. The international pharmaceutical formulations product portfolio includes innovative prescription products in niche therapeutic areas such as Pain, Diabetes & Cardiovascular management, Oncology, Renal Disease, Osteoporosis management and Gastro-intestinal care. 

Read also: Panacea, SII conducting trials to develop dengue vaccine: DG ICMR

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News